EnglishFrenchGermanItalianSpanish

WELCOME TO THE NEWSROOM

WATCH OUR LATEST VIDEO

In the news

Find our most recent press releases and other media below. CONTACT US if you need more details, would like to set up an interview or are a media person on deadline.

– High throughput system provides STAT results in about 80 minutes – March 31, 2020 (Ann Arbor, Michigan) NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing high throughput testing solutions to hospital and commercial reference laboratories, announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for...

March 12, 2020 (Ann Arbor, Michigan)  NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing testing solutions to hospital and commercial reference laboratories, announced today its plans for a SARS-CoV-2 Assay for use on its high throughput, fully automated NeuMoDx™ 288 and 96 Molecular Systems.  SARS-CoV-2 is the Coronavirus that has been determined to...

Ann Arbor, MI USA and Milan, Italy (November 25, 2019) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on developing testing solutions for hospital and commercial reference laboratory customers, and Sentinel Diagnostics, a leading company engaged in the development and production of diagnostic kits for Clinical Chemistry, Immunochemistry and Molecular Biology, announced today their...

NeuMoDx™ Molecular recently presented the evaluation of DiaSorin Molecular Enterovirus (EV) Primer Pair and Cytomegalovirus (CMV) Primer Pair in Laboratory Developed Test (LDT) Implementation on the open, random-access NeuMoDx™ 288 Molecular System at the Association for Molecular Pathology’s conference held in Baltimore Maryland. Michelle Mastronardi (Director, Systems Integration at NeuMoDx Molecular), along with Stephen Young,...












































































Coronavirus Assay Information

NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing testing solutions to hospital and commercial reference laboratories, has developed a SARS-CoV-2 Assay for use on the high throughput, fully automated NeuMoDx™ 288 and 96 Molecular Systems. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the NeuMoDx™ SARS-CoV-2 Assay implemented on the NeuMoDx™ Molecular Systems.

To learn more about SARS-CoV-2 testing, click here.
To order, click here.